STAAR Surgical Free Cash Flow 2012-2026 | STAA
STAAR Surgical free cash flow from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| STAAR Surgical Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | -7.67 |
| 2023 | -3.59 |
| 2022 | 17.61 |
| 2021 | 30.32 |
| 2020 | 12.55 |
| 2019 | 15.70 |
| 2018 | 10.52 |
| 2017 | 1.81 |
| 2016 | -2.16 |
| 2015 | -4.21 |
| 2014 | -12.01 |
| 2013 | -0.09 |
| 2012 | 0.95 |
| 2011 | 4.41 |
| STAAR Surgical Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | -34.46 |
| 2025-06-30 | -36.24 |
| 2025-03-31 | -7.20 |
| 2024-12-31 | -7.67 |
| 2024-09-30 | -2.59 |
| 2024-06-30 | -0.17 |
| 2024-03-31 | 16.48 |
| 2023-12-31 | -3.59 |
| 2023-09-30 | -32.48 |
| 2023-06-30 | -17.32 |
| 2023-03-31 | -8.00 |
| 2022-12-31 | 17.61 |
| 2022-09-30 | 18.66 |
| 2022-06-30 | 0.83 |
| 2022-03-31 | -7.15 |
| 2021-12-31 | 30.32 |
| 2021-09-30 | 26.51 |
| 2021-06-30 | 7.47 |
| 2021-03-31 | 4.61 |
| 2020-12-31 | 12.55 |
| 2020-09-30 | -4.86 |
| 2020-06-30 | -12.40 |
| 2020-03-31 | -10.36 |
| 2019-12-31 | 15.70 |
| 2019-09-30 | 8.83 |
| 2019-06-30 | -0.39 |
| 2019-03-31 | -1.47 |
| 2018-12-31 | 10.52 |
| 2018-09-30 | 8.70 |
| 2018-06-30 | 1.04 |
| 2018-03-31 | 1.57 |
| 2017-12-31 | 1.81 |
| 2017-09-30 | 0.77 |
| 2017-06-30 | -1.99 |
| 2017-03-31 | -0.94 |
| 2016-12-31 | -2.16 |
| 2016-09-30 | -1.79 |
| 2016-06-30 | -2.46 |
| 2016-03-31 | -3.99 |
| 2015-12-31 | -4.21 |
| 2015-09-30 | -1.60 |
| 2015-06-30 | -2.10 |
| 2015-03-31 | -2.54 |
| 2014-12-31 | -12.01 |
| 2014-09-30 | -6.88 |
| 2014-06-30 | -6.27 |
| 2014-03-31 | -4.01 |
| 2013-12-31 | -0.09 |
| 2013-09-30 | 0.44 |
| 2013-06-30 | -1.66 |
| 2013-03-31 | -1.65 |
| 2012-12-31 | 0.95 |
| 2012-09-30 | 2.55 |
| 2012-06-30 | 0.40 |
| 2012-03-31 | -0.72 |
| 2011-12-31 | 4.41 |
| 2011-09-30 | 4.71 |
| 2011-06-30 | 2.73 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $1.309B | $0.239B |
| Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| Becton Dickinson (BDX) | United States | $43.913B | 11.10 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |